ValiRx plc (FRA:EAJF)

Germany flag Germany · Delayed Price · Currency is EUR
0.0005
0.00 (0.00%)
At close: Dec 4, 2025
-96.67%
Market Cap 2.76M
Revenue (ttm) 58.07K
Net Income (ttm) -2.08M
Shares Out n/a
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 5,500
Open 0.0005
Previous Close 0.0005
Day's Range 0.0005 - 0.0005
52-Week Range 0.0005 - 0.0195
Beta n/a
RSI 8.99
Earnings Date May 26, 2026

About ValiRx

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. It also develops VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; BC201,... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Employees 14
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol EAJF
Full Company Profile

Financial Performance

In 2024, ValiRx's revenue was 49,775, an increase of 418.49% compared to the previous year's 9,600. Losses were -1.92 million, -5.99% less than in 2023.

Financial numbers in GBP Financial Statements

News

There is no news available yet.